Valuation: OneSource Specialty Pharma Limited

Market Cap 184B 1.92B 1.68B 1.59B 1.45B 2.71B 2.73B 19.01B 7.36B 93.86B 7.2B 7.04B 302B P/E 2027 *
39.6x
P/E 2028 * 19.1x
Enterprise Value 193B 2.01B 1.76B 1.67B 1.52B 2.84B 2.86B 19.93B 7.72B 98.39B 7.54B 7.38B 316B EV / Sales 2027 *
8.83x
EV / Sales 2028 * 5.44x
Free-Float
64.51%
Yield 2027 *
-
Yield 2028 * -
1 day+0.50%
1 week+0.48%
Current month+5.50%
1 month+8.02%
3 months+2.99%
6 months+20.13%
Current year-11.49%
1 week 1,567
Extreme 1567
1,643
1 month 1,504.1
Extreme 1504.1
1,657.5
Current year 1,057
Extreme 1057
1,917.8
1 year 1,057
Extreme 1057
1,925
3 years 1,057
Extreme 1057
2,248
5 years 1,057
Extreme 1057
2,248
10 years 1,057
Extreme 1057
2,248
Manager TitleAgeSince
Chief Executive Officer 54 29/02/2024
Director of Finance/CFO - 03/07/2024
Compliance Officer - 13/03/2023
Director TitleAgeSince
Chairman 65 21/09/2025
Director/Board Member 54 29/02/2024
Director/Board Member 66 26/02/2025
Change 5-day change 1-year change 3-year change Capi.($)
+0.50%+0.48%-10.46% - 1.92B
-0.14%+4.33%+9.00%+31.64% 47.97B
-1.69%+1.48%+50.57%+34.53% 44.5B
+2.56%+7.34%+366.69%+608.26% 43.93B
+0.24%+2.85%+10.67%+94.47% 41.03B
-0.62%-1.11%+4.65%+48.91% 29.85B
-0.28%+1.07%+24.58%+155.58% 17.27B
+3.37%+9.21%+8.32% - 15.34B
-0.46%+1.20%+26.90%+42.21% 15.3B
-2.21%-4.70% - - 14.82B
Average +0.13%+2.16%+54.55%+145.08% 27.19B
Weighted average by Cap. +0.11%+2.85%+79.00%+160.28%

Financials

2027 *2028 *
Net sales 21.8B 227M 200M 188M 172M 322M 324M 2.26B 874M 11.14B 854M 835M 35.79B 34.02B 355M 311M 294M 268M 502M 505M 3.52B 1.36B 17.38B 1.33B 1.3B 55.86B
Net income 4.46B 46.52M 40.82M 38.56M 35.14M 65.78M 66.24M 461M 179M 2.28B 175M 171M 7.32B 8.97B 93.57M 82.11M 77.55M 70.67M 132M 133M 928M 359M 4.58B 351M 344M 14.73B
Net Debt 8.86B 92.4M 81.08M 76.58M 69.79M 131M 132M 916M 355M 4.52B 347M 339M 14.54B 1.16B 12.14M 10.66M 10.07M 9.17M 17.17M 17.29M 120M 46.65M 595M 45.6M 44.61M 1.91B
Logo OneSource Specialty Pharma Limited
OneSource Specialty Pharma Limited is an India-based Contract Development and Manufacturing Organization (CDMO). The Company offers end-to-end CDMO services across all phases of pre-clinical and clinical development and commercial supply. The Company focuses on the development and manufacturing of complex pharmaceutical products including biologics, drug-device combinations, sterile injectables, and oral technologies (soft gelatine capsules). It supports the development of complex biologics, including microbial and mammalian cell line biopharmaceuticals, cell and gene therapy and ribonucleic acid (RNA) products. Its integrated services offer comprehensive biologics solutions. The Company develops a variety of soft gelatin capsules including traditional and enteric softgels, vegan capsule alternatives, chewable formats and specialty dosage forms, and liposomal systems and applicaps. It also provides end-to-end development and manufacturing of sterile injectable products.
Employees
1,674
Date Price Change Volume
25/09/26 ₹1,602.60 +0.50% 227,395
24/09/26 ₹1,594.60 -0.13% 104,912
23/09/26 ₹1,596.70 +0.55% 158,650
22/09/26 ₹1,587.90 -0.71% 155,059
21/09/26 ₹1,599.20 +0.27% 319,894
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1,602.60INR
Average target price
2,056.00INR
Spread / Average Target
+28.29%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ONESOURCE Stock